Vor BioPharma (VOR.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov19

H.C. Wainwright Maintains Buy Rating on Vor Biopharma

15:22

Nov14

Vor BioPharma released FY2025 9 Months Earnings on November 13 EST, with actual revenue of USD 0 and EPS of USD -378.0731

04:00

Vor BioPharma released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -121.63 (forecast USD -2.9)

04:00

Nov13

Vor Biopharma Announces Equity Offering and Stock Plunges

04:16

Nov8

Vor Bio's Drug Telitacicept Reaches Primary Endpoint in IgA Nephropathy Clinical Trial

16:46

Oct29

Vor Biopharma Inc's TELITACICEPT Shows Good Efficacy and Safety in Myasthenia Gravis Trial

15:44

Schedules & Filings

Schedules

Filings

Nov13

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -812.68 M, EPS -121.6266

Sep19

Reverse Stock Split(EST)

1-for-20 Reverse Stock Split

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -1.574 B, EPS -251.2414

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change